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Background: Neurocognitive impairments are a core feature of psychosis and major depressive disorder (MDD) and are associated with poorer functioning outcomes in these illnesses. Individuals at ultra-high risk (UHR) for psychosis have been shown to experience mild but significant cognitive impairments relative to healthy controls. Evidence suggests neurocognitive deficits are useful predictors of transition to psychotic disorder, although there is inconsistency regarding the specific domains implicated. Furthermore, depression is common in the UHR population, but the relationship between neurocognitive impairment and depression in UHR has not been investigated. The aim of this study was to examine neurocognitive functioning in UHR participants at baseline and whether neurocognitive performance is associated with i) transition to psychosis; ii) depressive disorder; and iii) functioning at medium-term follow-up (median 24 months). Methods: Secondary analysis of data collected as part of a multi-centre RCT of omega-3 fatty acids and cognitive behavioural case management (NEURAPRO) for individuals at UHR for psychosis was conducted. Baseline, 6, 12 and 24-month (median) assessments relevant to the current study included the Comprehensive Assessment of the At-Risk Mental State (CAARMS), Structured Clinical Interview for DSM-IV (SCID), Brief Assessment of Cognition for Schizophrenia (BACS), MontgomeryÅsberg Depression Rating Scale (MADRS) and Social and Occupational Functioning Assessment Scale (SOFAS). The analysis was conducted on the 287 UHR participants (129 males, 158 females) who completed these measures. Hierarchical Cox proportional hazards regression was used to examine neurocognitive predictors of transition to psychosis, while hierarchical logistic and linear regressions were used to identify neurocognitive predictors of MDD and functioning, respectively. Results: Mean z-scores at baseline indicated that the UHR participants performed on average a quarter to half a standard deviation below healthy people in most domains (range mean z=-0.24 to -0.47), except for executive functioning (mean z=0.16, SD=1.21). One hundred and nineteen (41.5%) participants met criteria for MDD at baseline. Thirty-eight (13.2%) participants transitioned to psychosis over 24 months. Results showed that poorer Executive (p=.01) and Motor (p=.03) functions were predictive of transition to psychosis over 24 months, after controlling for other clinical and treatment variables. Forty-eight (16.7%) participants met criteria for MDD at 24 months. Faster Processing Speed significantly predicted MDD at 24 months (p=.01), but failed to retain significance after controlling for other factors, with baseline and past MDD history emerging as the strongest predictors of MDD at medium-term follow-up (both p<.001). After adjustment for IQ and baseline functioning, functional outcomes at 6, 12 and 24 months were predicted by baseline Processing Speed. Discussion: These findings suggest that neurocognitive abilities are important predictors of transition to psychosis and functional outcomes within the UHR population, but hold minimal value in predicting MDD after controlling for history of MDD. Further research is needed that examines trajectory of neurocognition over time in UHR and in relation to psychopathology and functioning outcomes. Background: Schizotypal disorder has been linked to conversion to schizophrenia, with a quarter to half of patients converting over a course of two to five years. Substance use disorders are common in patients with schizotypal disorder, and cannabis has been shown to be a risk factor for developing schizotypal disorder. Cannabis has also been linked to an increased risk of schizophrenia. Other substance use disorders, in particular alcohol, may also increase risk of later schizophrenia. These previous results suggest that substance use, in particular cannabis, may predict conversion to schizophrenia in people with schizotypal disorder. Methods: We used the nationwide, unselected Danish registers. The study population was all people born since 1981 in Denmark with incident diagnosis of schizotypal disorder, without previous diagnosis of schizophrenia. Information on substance use disorders was combined from five different registers. Cox regression using time-varying information on substance use disorders and antipsychotic medication, and adjusted for parental history of mental disorders, sex, birth year, and calendar year were used to estimate hazard ratios (HR) and 95% confidence intervals (CI). Results: After two years, 16.3% (95% CI 14.8%-17.8%) of the people with schizotypal disorder had converted to schizophrenia. After 20 years, the conversion rate was 33.1% (95% CI 29.3-37.3) overall, and 58.2% (95% CI 44.8%-72.2%) in those with cannabis use disorders. In fully adjusted models, any substance use disorder predicted conversion to schizophrenia (HR=1.34, 95% CI 1.11-1.63). Dividing by substances, cannabis use disorders (HR=1.30, 95% CI 1.01-1.68), amphetamine use disorders (HR=1.90, 95% CI 1.14-3.17), and opioid use disorders (HR=2.74, 95% CI 1.38-5.45) predicted conversion to schizophrenia. These associations were not explained by concurrent use of antipsychotic medication, functional level before incident schizotypal disorder, or parental history of mental disorders. Discussion: Substance use disorders, in particular cannabis, amphetamines, and opioids, are important predictors of conversion from schizotypal disorder to schizophrenia. However, conversion rates are high even in those without substance use disorders, indicating a need for both universal and substance-targeted prevention in people with schizotypal disorder.
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